Measles vaccines. A review of adverse events

Drug Safety

Volumn 19, Issue 6, 1998, Pages 435-454

  Duclos, Philippe ^a,c   Ward, Brian J ^b  

^a LAB CENTRE FOR DISEASE CONTROL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EGG PROTEIN; GELATIN; MEASLES VACCINE;

ANAPHYLAXIS; AUTISM; CONJUNCTIVITIS; CROHN DISEASE; DATA ANALYSIS; DRUG FATALITY; ENCEPHALOMYELITIS; FEBRILE CONVULSION; FEVER; GUILLAIN BARRE SYNDROME; HUMAN; INFECTION CONTROL; INSULIN DEPENDENT DIABETES MELLITUS; MEASLES; MEASLES VACCINATION; MYELITIS; OPTIC NERVE DISEASE; PANENCEPHALITIS; PERCEPTION DEAFNESS; PRIORITY JOURNAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIC PURPURA; ULCERATIVE COLITIS; UNITED KINGDOM;

CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGIC STUDIES; HUMANS; INFANT; MEASLES; MEASLES VACCINE;

EID: 0032432648     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199819060-00002     Document Type: Review

References (135)

1. Expanded Programme on Immunization (EPI). Progress towards global measles control and elimination, 1990-1996. Wkly Epidemiol Rec 1997; 72: 349-53
2. de Quadros CA, Olivé JM, Hersh BS, et al. Measles elimination in the Americas: evolving strategies. JAMA 1996; 275: 224-9
3. Centers for Disease Control and Prevention. Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization and CDC. MMWR Morb Mortal Wkly Rep 1997; 46 (No. RR-11): 1-21
4. Thompson NP, Montgomery SM, Pounder RW, et al. Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 1995; 345: 1071-4
5. Wakefield AJ, Murch SH, Anthony A, et al. Illeal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351: 637-41
6. Begg N, Ramsay M, White J, et al. Media dents confidence in MMR vaccine. BMJ 1998; 316: 561
7. Markowitz LE, Katz SL. Measles vaccine. In: Plotkin SA, Mortimer EA, Vaccines, 2nd ed. Philadelphia: WB Saunders Company, 1994: 229-76
8. Aaby P, Samb B, Simondon F. et al. A comparison of vaccine efficacy and mortality during routine use of high-titre Edmonston-Zagreb and Schwarz standard measles vaccines in rural Senegal. Trans R Soc Trop Med Hyg 1996; 90: 326-30
9. Aaby P, Samb B, Simondon F, et al. Sex specific mortality after high titre measles vaccines in rural Senegal. Bull World Health Organ 1994; 72: 761-70
10. Aaby P, Knudsen K, Whittle H, et al. Long-term survival after Edmonston-Zagreb measles vaccination: increased female mortality. J Pediatr 1993; 122: 904-8
11. Holt EA, Moulton LH, Siberry GK, et al. Differential mortality by measles vaccine titre and sex. J Infect Dis 1993; 168: 1087-96
12. Safety of high titre measles vaccines. Wkly Epidemiol Rec 1992; 67: 357-61
13. Diaz-Ortega JL, Luna-Abascal M, Valdespino JL, et al. Mortality and morbidity after high titre measles vaccine in Mexico. Lancet 1992; 340: 924
14. Griffin DE, Ward BJ, Esolen LM. Pathogenesis of measles virus infection: an hypothesis for altered immune responses. J Infect Dis 1994; 170 Suppl. 1: S24-31
15. Hussey GD, Goddard EA, Hughes J, et al. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune responses in infants. J Infect Dis 1996; 1973: 1320-26
16. Karp CL, Wysocka M, Wahl LM, et al. Mechanisms of suppresssion of cell-mediated immunity by measles virus. Science 1996; 273: 228-31
17. Starr SE. Novel mechanism of immunosuppression after measles. Lancet 1996; 348: 1257-8
18. Auwaerter PG, Hussey GD, Goddard EA, et al. Changes within T cell receptor Vb subsets in infants following measles vaccination. Clin Immunol Immunopathol 1996; 79: 163-70
19. Stratton RS, Howe CJ, Johnston Jr RB. Adverse events associated with childhood vaccines: evidence bearing on causality. Washington, DC: National Academy Press, 1994
20. Slater PE, Ben-Zvi T, Fogel A, et al. Absence of an association between rubella vaccination and arthritis in underimmune postpartum women. Vaccine 1995; 13: 1529-32
21. Tingle AJ, Mitchell LA, Grace M, et al. Randomized double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women. Lancet 1997; 349: 1277-81
22. Ray P, Black S, Shinefield H, et al. Risk of chronic arthropathy among women after rubella vaccination. JAMA 1997; 278: 551-6
23. Slater P. Chronic arthropathy after rubella vaccination in women: false alarm? [letter]. JAMA 1997; 278: 594-5
24. Surveillance of adverse events following immunization. Wkly Epidemiol Rec 1996; 71: 237-42
25. Institute of Medicine. Adverse effects of pertussis and rubella vaccines. Washington, DC: National Academy Press, 1991
26. Expert Committee on Biological Standardization: Forty-third Report. WHO Technical Report Series 840. Geneva: World Health Organization, 1994
27. Böni J, Stalder J, Reigel F, et al. Detection of reverse transcriptase activity in live attenuated virus vaccines. Clin Diagn Virol 1996; 5: 43-53
28. Weissmahr RN, Schüpbach J, Böni J. Reverse transcriptase activity in chicken embryo fibroblast culture supernatants is associated with particles containing endogenous avian retrovirus EAV-0 RNA. J Virol 1997; 71: 3005-12
29. Report of a WHO consultation on issues related to the presence of reverse transcriptase activity in chick-cell derived vaccines. Wkly Epidemiol Rec 1998; 73: 209-12
30. Robertson JS, Minor P. Reverse transcriptase activity in vaccines derived from chick cells. Biologicals 1996; 24: 289-90
31. Kahn AS, Maudru T, Thompson A, et al. The reverse transcriptase activity in cell-free medium of chicken embryo fibroblast cultures is not associated with a replication-competent retrovirus. J Clin Virol 1998; 11: 7-13
32. Robertson JS, Nicolson C, Riley AM, et al. Assessing the significance of reverse transcriptase activity in chick cell-derived vaccines. Biologicals 1997; 25: 403-14
33. Waters TD, Beebe GW, Miller RW. Yellow fever vaccination, avian leukosis virus, and cancer risk in man. Science 1972; 177: 76-7
34. Sciberras J. Adverse vaccine events and adrenaline use in the Ontario measles immunization campaign. Public Health and Epidemiology Report (PHERO) 1996; 7: 400-7
35. Skinner R, Christie P, Cowden JM. The measles/rubella immunisation campaign in Scotland. Health Bull 1996; 54: 88-98
36. Peltola H, Heinonen O. Frequency of true adverse reactions to measles-mumps-rubella vaccine. Lancet 1986; 1: 939-42
37. Centres for Disease Control. Adverse events following immunization. Atlanta: US Department of Health and Human Services, Public Health Service, CDC, 1989. Surveillance Report no.: 3, 1985-1986
38. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345: 567-9
39. Advisory Committee on Immunization Practices (ACIP). Update: vaccine side effects, adverse reactions, contraindications, and precautions. MMWR Morb Mortal Wkly Rep 1996; 45 (RR12): 1-35
40. James JM, Burks AW, Robertson PK, et al. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995; 332: 1262-6
41. Freigang B, Jadvji TP, Freigang DW. Lack of adverse reactions to measles, mumps, and rubella vaccine in egg-allergic children. Ann Allergy 1994; 73: 486-8
42. Fasano MB, Wood RA, Cooke SK, et al. Egg hypersensitivity and adverse reactions to measles, mumps, and rubella vaccine. J Pediatr 1992; 120: 878-81
43. Baxter DN. Measles immunization in children with a history of egg allergy. Vaccine 1996; 14: 131-4
44. National Advisory Committee on Immunization (NACI). Supplementary statement MMR vaccine and anaphylactic hypersensitivity to egg or egg-related antigens. Can Commun Dis Rep 1996; 22-14: 113-5
45. Sakagushi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol 1996; 98: 1058-61
46. Griffin DE, Bellini WJ. Measles virus. In: Fields BN, Knipe DM, Howley PM, et al. Field's Virology. 3rd ed. Philadelphia Lippincott Raven Publishers, 1996; 1: 1267-312
47. Miller D, Wadsworth J, Diamond J, et al. Measles vaccination and neurological events. Lancet 1997; 349: 730-1
48. Montgomery SM, Wakefield AJ. Measles vaccine and neurological events. Lancet 1997; 349: 1625
49. Miller D, Ross E, Wadsworth J, et al. Measles vaccine and neurological events: authors' reply. Lancet 1997; 349: 1625-6
50. Black S, Shinefield H, Ray P, et al. Risk of hospitalisation because of aseptic meningitis after measles-mumps-rubella vaccination in one-to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatr Infect Dis J 1997; 16: 500-3
51. Weibel RE, Caserta V, Benor DE, et al. Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: a review of claims submitted to the National Vaccine Injury Compensation Program. Pediatrics 1998; 101: 383-7
52. Pless R, Duclos P, and the Advisory Committee on Causality Assessment. Reinforcing surveillance for vaccine-associated adverse events: the advisory committee on causality assessment. Can J Infect Dis 1996; 7: 98-9
53. Division of Immunization. Canadian national report on immunization, 1996. Can Commun Dis Rep 1997; 23S4: 1-50
54. Jayarajan V, Sedler PA. Hearing loss following measles vaccination [letter]. J Infect 1995; 30: 194-5
55. Booth JB. Sudden and fluctuant sensorineural hearing loss. In: Kerr AG, editor. Scott-Brown's otolaryngology: vol. 3: Otology, London: Butterworths, 1987: 387-434
56. Stevenson VL, Acheson JF, Ball J, et al. Optic neuritis following measles/rubella vaccination in two 13-year-old children. Br J Ophtalmol 1996; 80: 1110-1
57. Modlin JF, Jabbour JT, Witte JJ, et al. Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis. Pediatrics 1977; 59: 505-12
58. Dyken PR, Cunningham SC, Ward LC. Changing character of subacute sclerosing panencephalitis in the United States. Pediatr Neurol 1980; 5: 339-41
59. Bellini WJ, Rota JS, Villamarzo YS, et al. Measles nucleotide sequences associated with recent cases of subacute sclerosing panencephalitis [abstract]. 16th Annual American Society for Virology Scientific Meeting: 1997 Jul 19-23; Bozeman, Montana
60. da Silveira CM, Salisbury DM, de Quadros CA. Measles vaccination and Guillain-Barré syndrome. Lancet 1997; 349: 14-6
61. Jonville-Béra AP, Autret E, Galy-Eyraud C, et al. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French Pharmacovigilance Centres and Pasteur-Mérieux Sérums et Vaccins. Pediatr Infect Dis J 1996; 15: 44-8
62. Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatr Infect Dis J 1996; 15: 88-90
63. Wakefield AJ, Pittilo RM, Sim R, et al. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol 1993: 39: 345-53
64. Ekbom A, Wakefield AJ, Zack M, et al. Perinatal measles infection and subsequent Crohn's disease. Lancet 1994; 344: 508-10
65. Lewin J, Dhillon AP, Sim R, et al. Persistent measles virus infection of the intestine: confirmation by immunogold electron microscopy. Gut 1995; 36: 564-9
66. Daszak P, Purcell M, Lewin J, et al. Detection and comparative analysis of persistent measles virus infection in Crohn's disease by immunogold electron microscopy. J Clin Pathol 1997; 50: 299-304
67. Miyamoto H, Tanaka T, Kitamoto N, et al. Detection of immunoreactive antigen with monoclonal antibody to measles virus in tissue from a patient with Crohn's disease. J Gastroenterol 1995; 30: 28-33
68. Knibbs DR, Van Kruiningen HJ, Colombel JF, et al. Ultrastructlural evidence of paramyxovirus in two French families with Crohn's disease [abstract]. Gastroenterology 1993; 104: A726
69. Ekbom A, Daszak P, Kraaz W, et al. Crohn's disease after in utero measles virus exposure. Lancet 1996; 348: 515-7
70. Ward B, DeWals P. Association between measles infection and the occurrence of chronic inflammatory bowel disease. Can Commun Dis Rep 1997; 23: 1-5
71. Minor PD. Measles vaccination as a risk factor for inflammatory bowel disease [letter]. Lancet 1995; 345: 1362-3
72. Liu Y, Van Kruiningen HJ, West AB, et al. Immunocytochemical evidence of Listeria, Escherichia coli and Streptococcus antigens in Crohn's disease. Gastroenterology 1995; 108: 1396-404
73. Haga Y, Funagoshi O, Kuroe K, et al. Absence of measles viral genomic sequences in intestinal tissues from Crohn's disease by nested polymerase chain reaction. Gut 1996; 38: 211-5
74. Afzal MA, Minor PD, Begley J, et al. Absence of measles-virus genome in inflammatory bowel disease [letter]. Lancet 1998; 351: 646-7
75. Iizuka M, Nakagomi O, Chiba M, et al. Absence of measles virus in Crohn's disease [letter]. Lancet 1995; 345: 199
76. Iizuka M, Masamune O. Measles vaccination and inflammatory bowel disease [letter]. Lancet 1997; 350: 1775
77. Touze I, Dubucquoi S, Cortot A, et al. IgM-specific measles-virus antibody in families with a high frequency of Crohn's disease. Lancet 1995; 346: 967
78. Fisher NC, Yee L, Nightingale P, et al. Measles virus serology in Crohn's disease. Gut 1997; 41: 66-9
79. Balzola FA, Castellino F, Colombatto P, et al. IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus-related disease? Eur J Gastroenterol Hepatol 1997; 9: 661-3
80. Patriarca PA, Beeler JA. Measles vaccination and inflammatory bowel disease [letter]. Lancet 1995; 345: 1062-3
81. Farrington P, Miller E. Measles vaccination as a risk for inflammatory bowel disease [letter]. Lancet 1995; 345: 1362
82. Calman KC. Measles vaccination as a risk for inflammatory bowel disease (reply) [letter]. Lancet 1995; 345: 1362
83. MacDonald TT. Measles vaccination as a risk factor for inflammatory bowel disease [letter]. Lancet 1995; 345: 1363
84. Miller D, Renton A. Measles vaccination as a risk factor for inflammatory bowel disease [letter]. Lancet 1995; 345: 1363
85. Baxter T, Radford J. Measles vaccination as a risk factor for inflammatory bowel disease [letter]. Lancet 1995; 345: 1363-4
86. Thompson NP, Montgomery SM, Pounder RE, et al. Is measles vaccination a risk factor for inflammatory bowel disease [letter]. Lancet 1995; 345: 1364
87. Thompson NP, Fleming DM, Pounder RE, et al. Crohn's disease, measles, and measles vaccination: a case-control failure. Lancet 1996; 347: 263
88. Expanded Programme on Immunization (EPI). Association between measles infection and the occurrence of chronic inflammatory bowel disease [editorial note]. Wkly Epidemiol Rec 1998; 73: 38-9
89. Nielsen LLW, Nielsen NM, Melbye M, et al. Exposure to measles in utero and Crohn's disease: a Danish register study. BMJ 1998; 316: 196-7
90. Hermon-Taylor J, Ford S, Sumar N, et al. Measles virus and Crohn's disease. Lancet 1995; 345: 922-3
91. Jones P, Fine P. Piracha S. Crohn's disease and measles [letter]. Lancet 1997; 349: 473
92. Feeney M, Clegg A, Winwood P, et al. A case-control study of measles vaccination and inflammatory bowel disease. Lancet 1997; 350: 764-6
93. Montgomery SM, Morris DL, Pounder RE, et al. Measles vaccination and inflammatory bowel disease [letter]. Lancet 1997; 350: 1774
94. Feeney M, Clegg A, Winwood P, et al. Measles vaccination and inflammatory bowel disease [letter]. Lancet 1997; 350: 1774
95. Thompson NP, Pounder RE, Wakefield AJ. Perinatal and childhood risk factors in inflammatory bowel disease: a case-control study. Eur J Gastroenterol Hepatol 1995; 7: 385-90
96. Gilat T, Hacohen D, Lilos P, et al. Childhood factors in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1987; 22: 1009-24
97. Metcalf J. Is measles infection associated with Crohn's disease? The current evidence does not prove a causal link. BMJ 1998; 316: 166
98. Calman K. Measles, measles mumps rubella (MMR) vaccine, Crohn's disease and autism: dear doctor letter from the Chief Medical Officer; 1998 Mar. PL/CMO/98/2
99. Lione A, Scialli AR. Perinatal exposure to measles virus and the risk of inflammatory bowel disease. Reprod Toxicol 1997; 11: 647-52
100. Sartor RB, Rath HC, Sellon RK. Microbial factors in chronic intestinal inflammation. Curr Opin Gastroenterol 1996; 12: 327-33
101. Fudenberg HH. Dialysable lymphocyte extract (DLyE) in infantile onset autism: a pilot study. Biotherapy 1996; 9: 143-7
102. Chen RT, DeStefano F. Vaccine adverse events: causal or coincidental? Lancet 1998; 351: 611-2
103. Lindley KJ, Milla PJ. Autism, inflammatory bowel disease, and MMR vaccine [letter]. Lancet 1998; 351: 907-8
104. Walker-Smith J, Hamilton JR, Walker WA. Practical pediatric gastroenterology. Toronto: Butterworths, 1983: 1-400
105. Lipson A, Bartram CI, Williams CB, et al. Barium studies and ileoscopy compared in children with suspected Crohn's disease. Clin Radiol 1990; 41: 5-8
106. Theander G, Tragardh B. Lymphoid hyperplasia of the colon in childhood. Acta Radiol 1976; 17: 611-2
107. Lee JW, Melgaard B, Clements CJ, et al. Autism, inflammatory bowel disease, and MMR vaccine [letter]. Lancet 1998;351:905
108. Gillberg C, Steffenburg S, Schaumann H. Is autism more common now than 10 years ago. Br J Psychiatry 19991; 158: 403-9
109. Wing L. Autism spectrum disorders: no evidence for or against an increase in prevalence. BMJ 1996; 312: 327-8
110. Fombonne E. Inflammatory bowel disease and autism. Lancet 1998; 351: 955
111. Payne C, Mason B. Autism, inflammatory bowel disease, and MMR vaccine [letter]. Lancet 1998; 351: 907
112. Peltola H, Patja A, Leinikki P, et al. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. Lancet 1998; 351: 1327-8
113. Department of Health, England and Wales. MMR vaccine is not linked to Crohn's disease or autism: conclusion of an expert scientific seminar. London, 1998. Press release 98/109 March 24
114. Blom L, Nystrom L, Dahlquist G. The Swedish childhood diabetes study: vaccinations and infections as risk determinants for diabetes in childhood. Diabetologia 1991; 34: 176-81
115. Aicardi J, Goutiere SF, Arsenio-Nunes ML, et al. Acute measles encephalitis in children with immunosuppression. Pediatrics 1977; 59: 232-9
116. Roos RP, Graves MC, Wollmann RL, et al. Immunologic and virologic studies of measles inclusion body encephalitis: the relationship to subacute sclerosing panencephalitis. Neurology 1981; 31: 1270-81
117. Mitus A, Enders JF, Craig JM, et al. persistence of measles virus and depression of antibody formation in patients with giant cell pneumonia after measles. N Engl J Med 1959; 261: 882-9
118. Siegel MM, Walter TK, Ablin AR. Measles pneumonia in childhood leukemia. Pediatrics 1977; 60: 38-40
119. Bitnun A, Shannon P, Durward PA, et al. measles inclusion body encephalitis caused by measles vaccine [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 Sep 24-27: San Diego, 134.
120. Angel JB, Udem SA, Snydman DR, et al. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep 1996; 45: 603-5
121. Angel JB, Walpita P, Lerch RA, et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med 1998; 129: 104-6
122. Centers for Disease Control and Prevention. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998; 47 (No. RR8): 1-58
123. Expanded Programme on Immunization. Immunization policy. Geneva: World Health Organization, 1995. Document WHO/EPI/GEN/95.03, rev. 1
124. National Advisory Committee on immunization (NACI). Interim advisory on measles revaccination of persons with acquired immunodeficiency syndrome (AIDS). Can Commun Dis Rep 1996; 22: 116-7
125. Canadian Immunization Guide. Can Commun Dis Rep 1998
126. Pelletier L, Chung P, Duclos P, et al. A benefit-cost analysis of two-dose measles immunization in Canada. Vaccine 1998; 16: 989-96
127. Anonymous. MMR vaccine coverage falls after adverse publicity. Commun Dis Rep CDR Wkly 1998; 8: 41,44
128. Nicoll A, Elliman D, Ross E. MMR vaccination and autism 1998: Déjà vu - pertussis and brain damage 1974? BMJ 1998; 316: 715-6
129. Bedford H, Booy R, Dunn D, et al. Autism, inflammatory bowel disease, and MMR vaccine [letter]. Lancet 1998; 351: 907
130. Beale AJ. Autism, inflammatory bowel disease, and MMR vaccine [letter]. Lancet 1998; 351: 906
131. O'Brien SJ, Jones IG, Christie P. Autism, inflammatory bowel disease, and MMR vaccine [letter]. Lancet 1998; 351; 906-7
132. Black D, Prempeh H, Baxter T. Autism, inflammatory bowel disease, and MMR vaccine [letter]. Lancet 1998; 351: 905-6
133. Horton R. Autism, inflammatory bowel disease, and MMR vaccine [letter]. Lancet 1998; 351: 907-8
134. Wakefield AJ. Autism, inflammatory bowel disease, and MMR vaccine [letter]. Lancet 1998; 351: 908
135. Murch S, Thomson M, Walker-Smith J. Autism. inflammatory bowel disease, and MMR vaccine [letter]. Lancet 1998; 351: 908